Floatz logo

Plasmid Encoded Il-12

Refractory Malignant Neoplasm

M.D. Anderson Cancer CentervaccinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

181 Active assets in the Refractory Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
CatalYm GmbH
Phase 2BB

View all 50 →

Same molecule, other indications

Plasmid Encoded Il-12 is also rated in:

human papilloma virus infectionDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
anal canal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →